Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CCCC
C4 THERAPEUTICS, INC.
NASDAQ
$3.85
▼ DOWN 6.10% (-0.25)

KEY STATISTICS

Market Cap$425.68 M
52w High$5.17
52w Low$1.69
Dividend Yield—
Frequency—
P/E-3.85
Volume1.82M
Shares Out.110.57M

COMPANY

LEADERSHIP

Andrew J. Hirsch
CHIEF EXECUTIVE
Andrew J. Hirsch

COMPENSATION 2026

Salary$694,925
Stock Awards$710,730
Incentive Plan Pay$573,313
All Other Comp.$14,000
Total$2,940,975

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 2, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
104

PRICE TARGET

Target High$20.00
Target Low$6.00
Target Median$10.00
Target Consensus$11.33

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$4.78M
NOV
5
THU

PRICE

$3.85 ▼ DOWN 6.10% (−$0.25)
$3.90$4.00$4.109:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.85

About C4 Therapeutics, Inc.

https://www.c4therapeutics.com ↗

C4 Therapeutics, Inc. is a clinical-stage biopharma developing novel protein degraders for cancer and neurodegenerative diseases, with lead candidates in Phase 1/2 targeting multiple cancers and collaborations with Roche, Biogen, and Calico.

INDUSTRY

Biotechnology

A PRODUCT C4 THERAPEUTICS, INC. IS KNOWN FOR

Cemsidomide (CFT7455)
Cemsidomide (CFT7455)

Cemsidomide, C4 Therapeutics' lead oral drug candidate, employs targeted protein degradation to treat multiple myeloma and non-Hodgkin's lymphomas.

COMPETITORS

COMPETITOR
ARVN COMPARE
GLUE COMPARE
KURA COMPARE
KYMR COMPARE
NRIX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
68
LISTED HERE
13
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.3M
IWM
0.01% · 2.6M
FESM
0.06% · 1.0M
SCHA
0.01% · 427.9K
DFAS
0.01% · 235.2K
PRFZ
0.03% · 206.5K
AVSC
0.02% · 177.0K
R2US.L
0.01% · 159.3K
SBIO
0.22% · 136.8K
XRSG.L
0.01% · 92.7K
RSSL
0.01% · 47.9K
URTY
0.00% · 4.1K
RESM
0.01% · 199

INSTITUTIONAL OWNERSHIP

SHARES OWNED
72.11%
HOLDERS
202
TOP 12 OF 202 · RANKED BY POSITION SIZE
Point72 Asset Management, L.P.
9.4M sh · $18.03M
Morgan Stanley
9.1M sh · $23.86M
Ra Capital Management, L.P.
8.0M sh · $21.04M
Blackrock, Inc.
7.9M sh · $36.88M
Lynx1 Capital Management LP
7.3M sh · $34.22M
Bain Capital Life Sciences Investors, LLC
7.2M sh · $18.86M
Soleus Capital Management, L.P.
7.1M sh · $15.66M
Orbimed Advisors LLC
5.2M sh · $11.62M
Wasatch Advisors LP
4.9M sh · $10.77M
Jpmorgan Chase & Co
4.7M sh · $20.65M
Blackrock Inc.
4.6M sh · $21.03M
Vanguard Group Inc
4.4M sh · $8.37M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
REYNO LEONARD
Sale · 7.4K shares
2026-07-10
★
OFFICER: CHIEF MEDICAL OFFICER
REYNO LEONARD
Purchase · 15.3K shares
2026-07-10
★
DIRECTOR
Anderson Kenneth Carl
Purchase · 2.6K shares
2026-07-01
★
DIRECTOR
GROGAN DONNA ROY
Purchase · 3.3K shares
2026-07-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 3
OUTPERFORM 1
BUY 1
5 GRADES IN THE LAST 12 MONTHS
Evercore ISI Group OUTPERFORM Barclays OVERWEIGHT Brookline Capital BUY Wells Fargo OVERWEIGHT Stephens & Co. OVERWEIGHT

SECTORS PEERS

PEERPRICE
OABI$4.47COMPARE
PEPG$3.08COMPARE
CDXS$1.59COMPARE
MOLN$4.50COMPARE
MIST$1.16COMPARE
IMDX$4.13COMPARE